Major Depressive Disorder Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Major Depressive Disorder Pipeline Drugs Analysis Report Overview
The major depressive disorder pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, late-to-mid-stage pipeline products with Phase transition success rate (PTSR), and likelihood of approval (LoA) for major depressive disorder (MDD). The report also analyzes the clinical and commercial landscapes of MDD and provides an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide and is characterized by single or recurrent major depressive episodes (MDEs). MDD is only diagnosed if an MDE is not better explained by a psychotic disorder such as schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other psychotic disorder, and if there is no history of hypomania or mania.
Which are the key regions in the major depressive disorder pipeline drugs market?
The key regions in the major depressive disorder pipeline drugs market are Asia-Pacific, Europe, Middle East & Africa, North America, and South & Central America. Of all the trials initiated in MDD over the past 10 years, single-country trials were most numerous in the North America.
Major depressive disorder pipeline drugs market, by regions
For more regional insights, download a free report sample
Which are the key development stages in the major depressive disorder pipeline drugs market?
The key development stage in the major depressive disorder pipeline drugs market are pre-registration, phase I, phase II, phase III, IND/CTA filed, preclinical, and discovery. Phase II has the highest share in the major depressive disorder pipeline drugs market.
Major depressive disorder pipeline drugs market, by development stage
For more development stage insights, download a free report sample
Which are the key molecule types in the major depressive disorder pipeline drugs market?
The key molecule types in the major depressive disorder pipeline drugs market are small molecule, biologic, and oligonucleotide. The majority of the drugs in pipeline development for MDD are small molecules.
Major depressive disorder pipeline drugs market, by molecule type
For more molecule type insights, download a free report sample
Which are the key MoA in the major depressive disorder pipeline drugs market?
The key MoA in the major depressive disorder pipeline drugs market are receptor agonist, receptor antagonist, transporter inhibitor, enzyme inhibitor, receptor modulator, transporter activator, ligand scavenger, protein and peptide activator. Most of the MDD pipeline drugs are receptor agonists and antagonists.
For more MoA insights, download a free report sample
Which are the key RoA in the major depressive disorder pipeline drugs market?
The key RoA in the major depressive disorder pipeline drugs market are oral, injection, inhalational, and topical. Of all the MDD pipeline drugs, the oral route is the most common route of administration.
For more RoA insights, download a free report sample
Which are the key sponsors in the major depressive disorder pipeline drugs market?
The key sponsors in the major depressive disorder pipeline drugs market are Johnson & Johnson, Forest Laboratories, Eli Lilly and Co, Otsuka Holdings Co Limited, Orion Corp, Yale University, Allergen Ltd, and others.
Major depressive disorder pipeline drugs market, by sponsors
To know more about sponsors, download a free report sample
Market report overview
Key regions | Asia-Pacific, Europe, Middle East & Africa, North America, and South & Central America |
Key development stage | Pre-Registration, Phase I, Phase II, Phase III, IND/CTA Filed, Preclinical, and Discovery |
Key molecule types | Small Molecule, Biologic, and Oligonucleotide |
Key RoA | Oral, Injection, Inhalational, and Topical |
Key MoA | Receptor Agonist, Receptor Antagonist, Transporter Inhibitor, Enzyme Inhibitor, Receptor Modulator, Transporter Activator, Ligand Scavenger, Protein and Peptide Activator |
Key sponsors | Johnson & Johnson, Forest Laboratories, Eli Lilly and Co, Otsuka Holdings Co Limited, Orion Corp, Yale University, Allergen Ltd, and others |
Scope
GlobalData’s Major Depressive Disorder: Competitive Landscape in 2022 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Major Depressive Disorder market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Major Depressive Disorder market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which are the key regions in the major depressive disorder pipeline drugs market?
The key regions in the major depressive disorder pipeline drugs market are Asia-Pacific, Europe, Middle East & Africa, North America, and South & Central America.
-
Which are the key development stage in the major depressive disorder pipeline drugs market?
The key development stage in the major depressive disorder pipeline drugs market are pre-registration, phase I, phase II, phase III, IND/CTA filed, preclinical, and discovery.
-
Which are the key molecule types in the major depressive disorder pipeline drugs market?
The key molecule types in the major depressive disorder pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Which are the key MoA in the major depressive disorder pipeline drugs market?
The key MoA in the major depressive disorder pipeline drugs market are receptor agonist, receptor antagonist, transporter inhibitor, enzyme inhibitor, receptor modulator, transporter activator, ligand scavenger, protein and peptide activator.
-
Which are the key RoA in the major depressive disorder pipeline drugs market?
The key RoA in the major depressive disorder pipeline drugs market are oral, injection, inhalational, and topical.
-
Which are the key sponsors in the major depressive disorder pipeline drugs market?
The key sponsors in the major depressive disorder pipeline drugs market are Johnson & Johnson, Forest Laboratories, Eli Lilly and Co, Otsuka Holdings Co Limited, Orion Corp, Yale University, Allergen Ltd, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.